Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Proof-of-Concept Study of GRC 17536 in Painful Diabetic Peripheral Neuropathy
2012-002320-33Phase 2Completed
- Sponsor
- Glenmark Pharmaceuticals SA
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic polyneuropathy (DPN) comparing GRC 17536 BID with Placebo (2 arms). Primary endpoint: Change in 24-hour average pain intensity. Started Jun 2012; status: completed.
02
Drugs
GRC-17536
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on 2012-002320-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002320-33.